TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

NCT06487663 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable
Cholangiocarcinoma Non-resectable
Liver Metastases
Liver Malignant Tumors

Interventions

PROCEDURE: TACE with ICI

Sponsor

Tianjin Medical University Cancer Institute and Hospital